Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins

Journal of Experimental Medicine

Volumn 203, Issue 4, 2006, Pages 995-1006

  Adhikary, Dinesh ^a   Behrends, Uta ^a   Moosmann, Andreas ^b   Witter, Klaus ^b   Bornkamm, Georg W ^a   Mautner, Josef ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; IMMEDIATE EARLY PROTEIN BZLF1; PROTEIN BALF4; PROTEIN BLLF1; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTIGEN DETECTION; ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SPECIFICITY; CELL TRANSFER; CONTROLLED STUDY; CYTOLYSIS; EPSTEIN BARR VIRUS; HELPER CELL; HUMAN; HUMAN CELL; INCUBATION TIME; INFECTION CONTROL; LATENT PERIOD; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TARGET CELL; VIRION; VIRUS INFECTION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; B-LYMPHOCYTES; CARRIER STATE; CELL LINE; CELLS, CULTURED; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; GLYCOPROTEINS; HERPESVIRUS 4, HUMAN; HUMANS; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL PROTEINS; VIRION;

EID: 33645859336     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20051287     Document Type: Article

References (48)

1. Rickinson, A.B., and E. Kieff. 2001. Epstein-Barr virus. In Fields Virology. Knipe, D.M., and Howley, P.M. editors. Lippincott-Raven, Philadelphia, PA. 2575-2627.
2. Kuppers, R. 2003. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. 3:801-812.
3. Young, L.S., and A.B. Rickinson. 2004. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer. 4:757-768.
4. Papesch, M., and R. Watkins. 2001. Epstein-Barr virus infectious mononucleosis. Clin. Otolaryngol. 26:3-8.
5. Tanner, J., J. Weis, D. Fearon, Y. Whang, and E. Kieff. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 50:203-213.
6. Thorley-Lawson, D.A., and A. Gross. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350:1328-1337.
7. Laichalk, L.L., and D.A. Thorley-Lawson. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79:1296-1307.
8. Kieff, E., and A.B. Rickinson. 2001. Epstein-Barr virus and its replication. In Fields Virology. Knipe, D.M., and Howley, P.M. editors. Lippincott-Raven, Philadelphia, PA. 2511-2573.
9. Rooney, C.M., C.A. Smith, C.Y. Ng, S. Loftin, C. Li, R.A. Krance, M.K. Brenner, and H.E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 345:9-13.
10. Heslop, H.E., and C.M. Rooney. 1997. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157:217-222.
11. Callan, M.F. 2004. The immune response to Epstein-Barr virus. Microbes Infect. 6:937-945.
12. + help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188:2199-2204.
13. + T cells in the antitumor immune response. J. Exp. Med. 188:2357-2368.
14. Keating, S., S. Prince, M. Jones, and M. Rowe. 2002. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules. J. Virol. 76:8179-8188.
15. Ressing, M.E., D. van Leeuwen, F.A. Verreck, S. Keating, R. Gomez, K.L. Franken, T.H. Ottenhoff, M. Spriggs, T.N. Schumacher, L.M. Hutt-Fletcher, et al. 2005. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J. Virol. 79:841-852.
16. + T cells during primary infection. J. Immunol. 170:2590-2598.
17. Landais, E., X. Saulquin, M. Bonneville, and E. Houssaint. 2005. Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected B cells following capture of BHRF1 antigen. J. Immunol. 175:7939-7946.
18. + T-cell clones. J. Virol. 65:3821-3828.
19. Sitki-Green, D., M. Covington, and N. Raab-Traub. 2003. Compartmentalization and transmission of multiple epstein-barr virus strains in asymptomatic carriers. J. Virol. 77:1840-1847.
20. McHeyzer-Williams, M., L. McHeyzer-Williams, J. Panus, R. Pogue-Caley, G. Bikah, D. Driver, and M. Eisenbraun. 2003. Helper T-cell-regulated B-cell immunity. Microbes Infect. 5:205-212.
21. + T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med. 187:1395-1402.
22. Jilg, W., C. Bogedain, H. Mairhofer, S.Y. Gu, and H. Wolf. 1994. The Epstein-Barr virus-encoded glycoprotein gp 110 (BALF 4) can serve as a target for antibody-dependent cell-mediated cytotoxicity (ADCC). Virology. 202:974-977.
23. Milosevic, S., U. Behrends, H. Christoph, and J. Mautner. 2005. Direct mapping of MHC class II epitopes. J. Immunol. Methods. 306:28-39.
24. Moosmann, A., N. Khan, M. Cobbold, C. Zentz, H.J. Delecluse, G. Hollweck, A.D. Hislop, N.W. Blake, D. Croom-Carter, B. Wollenberg, et al. 2002. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood. 100:1755-1764.
25. Kempkes, B., D. Pich, R. Zeidler, B. Sugden, and W. Hammerschmidt. 1995. Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. J. Virol. 69:231-238.
26. Carel, J.C., B.L. Myones, B. Frazier, and V.M. Holers. 1990. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J. Biol. Chem. 265:12293-12299.
27. Wendtner, C.M., C. Kurzeder, H.D. Theiss, D.M. Kofler, J. Baumert, H.J. Delecluse, A. Janz, W. Hammerschmidt, and M. Hallek. 2003. High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors. Exp. Hematol. 31:99-108.
28. Prodinger, W.M., M.G. Schwendinger, J. Schoch, M. Kochle, C. Larcher, and M.P. Dierich. 1998. Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21). J. Immunol. 161:4604-4610.
29. + T cells by recombinant influenza viruses. Eur. J. Immunol. 33:3331-3341.
30. Lee, S.P., L.E. Wallace, M. Mackett, J.R. Arrand, P.F. Searle, M. Rowe, and A.B. Rickinson. 1993. MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways. Int. Immunol. 5:451-460.
31. Bickham, K., K. Goodman, C. Paludan, S. Nikiforow, M.L. Tsang, R.M. Steinman, and C. Munz. 2003. Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro. J. Exp. Med. 198:1653-1663.
32. + killer T cells. J. Exp. Med. 193:405-411.
33. Alfieri, C., M. Birkenbach, and E. Kieff. 1991. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 181:595-608.
34. Babcock, G.J., L.L. Decker, R.B. Freeman, and D.A. Thorley-Lawson. 1999. Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190:567-576.
35. Baldanti, F., P. Grossi, M. Furione, L. Simoncini, A. Sarasini, P. Comoli, R. Maccario, R. Fiocchi, and G. Gerna. 2000. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J. Clin. Microbiol. 38:613-619.
36. Montone, K.T., R.L. Hodinka, K.E. Salhany, E. Lavi, A. Rostami, and J.E. Tomaszewski. 1996. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease. Mod. Pathol. 9:621-630.
37. Tao, Q., K.D. Robertson, A. Manns, A. Hildesheim, and R.F. Ambinder. 1998. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood. 91:1373-1381.
38. + EBV-specific CTLs. J. Immunol. 158:3619-3625.
39. Staege, M.S., S.P. Lee, T. Frisan, J. Mautner, S. Scholz, A. Pajic, A.B. Rickinson, M.G. Masucci, A. Polack, and G.W. Bornkamm. 2002. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc. Natl. Acad. Sci. USA. 99:4550-4555.
40. Paludan, C., K. Bickham, S. Nikiforow, M.L. Tsang, K. Goodman, W.A. Hanekom, J.F. Fonteneau, S. Stevanovic, and C. Munz. 2002. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593-1603.
41. Morgan, A.J., M. Mackett, S. Finerty, J.R. Arrand, F.T. Scullion, and M.A. Epstein. 1988. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J. Med. Virol. 25:189-195.
42. Morgan, A.J., and A.D. Wilson. 1997. Epstein-Barr virus gp350 vaccines. EBV Rep. 4:33-39.
43. Thorley-Lawson, D.A., and C.A. Poodry. 1982. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43:730-736.
44. Wilson, A.D., M. Shooshstari, S. Finerty, P. Watkins, and A.J. Morgan. 1996. Virus-specific cytotoxic T cell responses are associated with immunity of the cottontop tamarin to Epstein-Barr virus (EBV). Clin. Exp. Immunol. 103:199-205.
45. + T helper cells. Eur. J. Immunol. 34:2500-2509.
46. Zuber, B., V. Levitsky, G. Jonsson, S. Paulie, A. Samarina, S. Grundstrom, S. Metkar, H. Norell, G.G. Callender, C. Froelich, and N. Ahlborg. 2005. Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J. Immunol. Methods. 302:13-25.
47. Granberg, C., K. Blomberg, I. Hemmila, and T. Lovgren. 1988. Determination of cytotoxic T lymphocyte activity by time-resolved fluorometry using europium-labelled concanavalin A-stimulated cells as targets. J. Immunol. Methods. 114:191-195.
48. Kimura, H., M. Morita, Y. Yabuta, K. Kuzushima, K. Kato, S. Kojima, T. Matsuyama, and T. Morishima. 1999. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J. Clin. Microbiol. 37:132-136.